Neuroimaging and Biochemical Markers in the Three Variants of Primary Progressive Aphasia

Background/Aim: To investigate in variants of primary progressive aphasia (PPA) the association between current clinical and neuroimaging criteria and biochemical/genetic markers at the individual level. Methods: Thirty-two PPA patients were classified as non-fluent/agrammatic (nfvPPA), semantic (svPPA), or logopenic variant (lvPPA) or as unclassifiable (uPPA). In all patients, we evaluated the neuroimaging criteria (magnetic resonance imaging and/or single photon emission computed tomography/positron emission tomography) of each variant and studied serum progranulin levels, APOE genotype and Alzheimer’s disease (AD)-cerebrospinal fluid (CSF) biomarkers. Cases with a first-degree family history of early-onset dementia were genetically tested. Results: Ten of 15 (66%) nfvPPA, 5/5 (100%) svPPA and 7/7 (100%) lvPPA patients showed at least one positive neuroimaging-supported diagnostic criterion. All lvPPA and 3/5 (60%) uPPA patients presented AD-CSF biomarkers, which were absent in nfvPPA and svPPA cases. Four (27%) nfvPPA patients had dementia-causing mutations: 2 carried a GRN mutation and 2 the C9ORF72 hexanucleotide expansion. Conclusions: There was an excellent association between clinical criteria and neuroimaging-supported biomarkers in svPPA and lvPPA, as well as with AD-CSF biochemical markers in the lvPPA. Neuroimaging, biochemical and genetic findings in nfvPPA were heterogeneous. Incorporating biochemical/genetic markers into the PPA clinical diagnosis would allow clinicians to improve their predictions of PPA neuropathology, especially in nfvPPA and uPPA cases.

[1]  J. Hodges,et al.  Semantic dementia. Progressive fluent aphasia with temporal lobe atrophy. , 1992, Brain : a journal of neurology.

[2]  B. Miller,et al.  The logopenic/phonological variant of primary progressive aphasia , 2008, Neurology.

[3]  David Heckerman,et al.  A Hexanucleotide Repeat Expansion in C9ORF72 Is the Cause of Chromosome 9p21-Linked ALS-FTD , 2011, Neuron.

[4]  P. Scheltens,et al.  Amyloid β(1–42) and phosphorylated tau in CSF as markers for early-onset Alzheimer disease , 2004, Neurology.

[5]  J. Molinuevo,et al.  Different profiles of Alzheimer’s disease cerebrospinal fluid biomarkers in controls and subjects with subjective memory complaints , 2011, Journal of Neural Transmission.

[6]  C. Jack,et al.  Characterizing a neurodegenerative syndrome: primary progressive apraxia of speech , 2012, Brain : a journal of neurology.

[7]  W. Klunk,et al.  Imaging brain amyloid in Alzheimer's disease with Pittsburgh Compound‐B , 2004, Annals of neurology.

[8]  David Mann,et al.  Frontotemporal lobar degeneration: clinical and pathological relationships , 2007, Acta Neuropathologica.

[9]  W. Jagust,et al.  Aβ amyloid and glucose metabolism in three variants of primary progressive aphasia , 2008, Annals of neurology.

[10]  Arthur L. Benton,et al.  Word fluency and brain damage , 1967 .

[11]  J. Hodges.  Alzheimer's disease and the frontotemporal dementias: contributions to clinico-pathological studies, diagnosis, and cognitive neuroscience. , 2012, Journal of Alzheimer's disease : JAD.

[12]  Jason D. Warren,et al.  Alzheimer's pathology in primary progressive aphasia , 2012, Neurobiology of Aging.

[13]  Nancy Johnson,et al.  Alzheimer and frontotemporal pathology in subsets of primary progressive aphasia , 2008, Annals of neurology.

[14]  B. Miller,et al.  An algorithm for genetic testing of frontotemporal lobar degeneration , 2011, Neurology.

[15]  M. Weiner,et al.  Cognition and anatomy in three variants of primary progressive aphasia , 2004, Annals of neurology.

[16]  E. Kaplan,et al.  The assessment of aphasia and related disorders , 1972 .

[17]  J. Molinuevo,et al.  Longitudinal Study of Amnesic Patients at High Risk for Alzheimer’s Disease: Clinical, Neuropsychological and Magnetic Resonance Spectroscopy Features , 2007, Dementia and Geriatric Cognitive Disorders.

[18]  Mari Yoshida,et al.  Neuropathological Investigation of Regions Responsible for Semantic Aphasia in Frontotemporal Lobar Degeneration , 2009, Dementia and Geriatric Cognitive Disorders.

[19]  Sébastien Ourselin,et al.  Progressive logopenic/phonological aphasia: Erosion of the language network , 2010, NeuroImage.

[20]  Eric Guedj,et al.  Phenotype variability in progranulin mutation carriers: a clinical, neuropsychological, imaging and genetic study. , 2008, Brain : a journal of neurology.

[21]  M. Mesulam,et al.  Quantitative template for subtyping primary progressive aphasia. , 2009, Archives of neurology.

[22]  Karalyn Patterson,et al.  Clinical and pathological characterization of progressive aphasia , 2006, Annals of neurology.

[23]  Theresa M. Harrison,et al.  Progression of language decline and cortical atrophy in subtypes of primary progressive aphasia , 2011, Neurology.

[24]  F. Pasquier,et al.  Prediction of pathology in primary progressive language and speech disorders , 2010, Neurology.

[25]  P. Scheltens,et al.  Amyloid beta(1-42) and phosphorylated tau in CSF as markers for early-onset Alzheimer disease. , 2004, Neurology.

[26]  M. Grossman,et al.  The non-fluent/agrammatic variant of primary progressive aphasia , 2012, The Lancet Neurology.

[27]  Johannes Kornhuber,et al.  Combined CSF tau, p-tau181 and amyloid-β 38/40/42 for diagnosing Alzheimer’s disease , 2009, Journal of Neural Transmission.

[28]  D. Neary,et al.  Distinct clinical and pathological characteristics of frontotemporal dementia associated with C9ORF72 mutations. , 2012, Brain : a journal of neurology.

[29]  P. Lewczuk,et al.  Cerebrospinal Fluid Tau, p-Tau 181 and Amyloid-β38/40/42 in Frontotemporal Dementias and Primary Progressive Aphasias , 2010, Dementia and Geriatric Cognitive Disorders.

[30]  Andrew Kertesz,et al.  The evolution and pathology of frontotemporal dementia. , 2005, Brain : a journal of neurology.

[31]  Karl Herholz,et al.  Clinical amyloid imaging in Alzheimer's disease , 2011, The Lancet Neurology.

[32]  M. Mesulam,et al.  Quantitative classification of primary progressive aphasia at early and mild impairment stages. , 2012, Brain : a journal of neurology.

[33]  Bruce L. Miller,et al.  Progressive Nonfluent Aphasia and Its Characteristic Motor Speech Deficits , 2007, Alzheimer disease and associated disorders.

[34]  Nick C Fox,et al.  Patterns of cortical thinning in the language variants of frontotemporal lobar degeneration , 2009, Neurology.

[35]  Kirrie J Ballard,et al.  Subtypes of progressive aphasia: application of the International Consensus Criteria and validation using β-amyloid imaging. , 2011, Brain : a journal of neurology.

[36]  K. Patterson,et al.  Primary progressive aphasia , 2012, Neurology.

[37]  B. Miller,et al.  Classification of primary progressive aphasia and its variants , 2011, Neurology.

[38]  J. Molinuevo,et al.  Serum progranulin levels in patients with frontotemporal lobar degeneration and Alzheimer's disease: detection of GRN mutations in a Spanish cohort. , 2012, Journal of Alzheimer's disease : JAD.

[39]  Jennifer L. Whitwell,et al.  Clinicopathological and imaging correlates of progressive aphasia and apraxia of speech. , 2006, Brain : a journal of neurology.

[40]  Nick C Fox,et al.  Frontotemporal dementia with the C9ORF72 hexanucleotide repeat expansion: clinical, neuroanatomical and neuropathological features , 2012, Alzheimer's & Dementia.

[41]  J. Hodges,et al.  Nuclear imaging can predict pathologic diagnosis in progressive nonfluent aphasia , 2007, Neurology.

[42]  Nick C Fox,et al.  The effect of APOE genotype on clinical phenotype in Alzheimer disease , 2006, Neurology.

[43]  Nick C Fox,et al.  Word-finding difficulty: a clinical analysis of the progressive aphasias. , 2007, Brain : a journal of neurology.

[44]  R. Nass,et al.  The assessment of aphasia and related disorders By Harold Goodglass and edith kaplan philadelphia, lea & febiger, 1983 illustrated, $27.50 (package) , 1984 .